WO2004069233A1 - 乳癌耐性蛋白阻害剤 - Google Patents
乳癌耐性蛋白阻害剤 Download PDFInfo
- Publication number
- WO2004069233A1 WO2004069233A1 PCT/JP2004/001054 JP2004001054W WO2004069233A1 WO 2004069233 A1 WO2004069233 A1 WO 2004069233A1 JP 2004001054 W JP2004001054 W JP 2004001054W WO 2004069233 A1 WO2004069233 A1 WO 2004069233A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- hydrogen atom
- bcrp
- cells
- compound
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Definitions
- the present invention relates to a breast cancer resistance protein (BCRP) inhibitor and an SN-38 resistant cancer cell useful for screening for a BCRP inhibitor.
- BCRP breast cancer resistance protein
- the drug-transporting protein P-glycoprotein encoded by the MDR1 gene discovered in the 1970's can overcome multidrug resistance by producing cross-resistance to multiple anticancer drugs with different chemical structures and mechanisms of action. It has been a potential target molecule for drugs.
- P-glycoprotein alone cannot explain the mechanism of resistance to anticancer drugs, and there is a need for the development of new drug-overcoming agents that target new drug transport proteins.
- BCRP breast cancer resistance protein
- ABS ATP-binding cassette
- BCRP has only one ATP-binding cassette in its structure, and is structurally different from P-glycoprotein and other drug transport proteins that have two ATP-binding cassettes.
- BCRP is a topoisomerase such as irinotecan hydrochloride (CPT-11) or topotecan I It is deeply involved in the mechanism of resistance to inhibitors and topoisomerase II inhibitors such as mitoxantrone.
- BCRP does not act on paclitaxel or pink listin excreted by P-glycoprotein, and CPT-11 and SN-38 (CPT-11 (Cancer Res. 59, 5938-5946 (1999)) and has been shown to have a different substrate specificity from P-glycoprotein. Furthermore, it has been suggested that BCRP is involved in the limitation of the bioavailability of orally administered anticancer drugs (J. Clin. Oncol. 20, 2943-2950 (2002)). Based on these facts, drugs that inhibit BCRP are expected to exert an effect of overcoming the resistance of anticancer drugs that could not be overcome by conventional resistance overcoming drugs, and also to improve the bioavailability of anticancer drugs, Its development is desired.
- An object of the present invention is to provide a cancer cell useful for screening a BCRP-inhibiting drug and a BCRP-inhibiting drug. Disclosure of the invention
- A549 cells which are cancer cells derived from human non-small cell lung cancer
- BCRP flaponoid compounds represented by the following formulas (1), (2), (3), (4) or (5)
- they have found that they have an inhibitory effect, and have completed the present invention.
- the present invention provides the following formula (1), (2), (3), (4) or (5):
- R 2 s may be the same or different, and represent a hydrogen atom, a hydroxyl group, a lower alkoxy group, a lower alkyl group. , a lower alkenyl group or showing a sugar residue, or be substituted with a lower alkyl group together with the adjacent R t rather it may also be formed a good pyran ring
- R 3 is a hydrogen atom, a hydroxyl group, a halogen atom, It represents a lower alkyl group, a lower alkoxy group, an amino group or a nitro group.
- R 4 represents a hydrogen atom, a hydroxyl group, a halogen atom, a lower alkoxy group, a lower alkyl group or a lower alkenyl group
- seven R 5 s may be the same or different
- a hydrogen atom, a hydroxyl group, a lower Represents an alkoxy group or a lower alkyl group, or two adjacent groups R 5 together may form a pyran ring which may be substituted with a lower alkyl group
- R 6 represents a hydrogen atom, a hydroxyl group, a halogen atom, a lower alkoxy group, a lower alkyl group, an amino group or a nitro group. Show. ]
- R 7 represents a hydrogen atom, a hydroxyl group, a halogen atom, a lower alkoxy group or a lower alkyl group
- two R 8 s may be the same or different, and represent a hydrogen atom, a hydroxyl group, a lower alkoxy group or a lower alkyl group.
- R 9 represents a hydrogen atom, a hydroxyl group, a halogen atom or a lower alkoxy group
- five R 1 (s) may be the same or different and represent a hydrogen atom, a hydroxyl group or a lower alkoxy group.
- R l2 represents a hydrogen atom or a lower alkenyl group
- R 13 represents a hydrogen atom or a hydroxyl group
- R 14 represents a hydrogen atom.
- a BCRP inhibitor comprising a flaponoid compound represented by the formula or a glycoside, ester or salt thereof as an active ingredient, an agent for overcoming an anticancer drug resistance to a cancer that has acquired resistance associated with BCRP, or expressing BCRP and having a low resistance to an anticancer agent It is intended to provide an agent for overcoming anticancer drug resistance to sensitive cancer.
- the present invention also provides an anticancer agent containing the above BCRP inhibitor and an anticancer agent that can be a substrate of BCRP.
- R 15 represents an amino group or a nitro group.
- the present invention provides SN-38 resistant human non-small cell lung cancer A549 cells that highly express BCRP. ' BRIEF DESCRIPTION OF THE FIGURES
- FIG. 1 is a graph showing the degree of A549 / SN-38-4 cell acquisition of resistance to SN-38 (A) and mitoxantrone (B).
- FIG. 2 is a diagram showing the results of analysis of mRNA expression of various drug transport proteins in A549 cells and A549 / SN-38 cells by RT-PCR.
- FIG. 3 shows the results of quantitative analysis of BCRP (A) and MRP2 (B) mRM expression in A549 cells and A549 / SN-38 cells by real-time RT-PCR.
- FIG. 4 is a graph showing the accumulated amounts of SN-38 (A) and SN-38 glucuronide conjugate (B) in A549 cells and A549 / SN-38-4 cells.
- FIG. 3B is a view showing the overcoming action of 3-4 (E) and compound 3-6 (F)].
- FIG. 6 is a graph showing the effect of a flaponoid compound on increasing SN-38 accumulation in P388 / BCRP cells.
- FIG. 7 is a graph showing the effect of flavonoid compounds on increasing SN-38 accumulation in MCF-7 cells.
- Human non-small cell lung cancer A549 cells are known to be easy to culture, can be transplanted into mice, and have high sensitivity to SN-38, the active form of CPT-11. (J. Clin. Inves t. 101, 1789-1796 (1998)). By continuously culturing the A549 cells while gradually increasing the SN-38 concentration in the medium, SN-38 resistant A549 cells were established. The obtained SN-38 resistant A549 cells, as shown in the Examples below, overexpress BCRP and have acquired resistance by reducing intracellular accumulation of SN-38. Useful for screening. SN-38 resistant A549 cells Can be used for in vitro screening, and can also be used for in vivo screening by transplantation into mice.
- the flaponoid compound of the present invention includes a flavone derivative represented by the above formula (1), a flavanone derivative represented by the formula (2), a chalcone derivative represented by the formula (3), an isoflavone derivative represented by the formula (4), or It is a flavonoid derivative represented by the formula (5).
- the lower alkoxy group represented by preferably has 1 to 4 carbon atoms, and particularly preferably a methoxy group.
- the lower alkyl group as preferably has 1 to 4 carbon atoms, and particularly preferably is a methyl group.
- the lower alkenyl group as R 2 , R 4 or R 12 in the formulas (1), (2) and (5) preferably has 2 to 5 carbon atoms, particularly 3-methyl-1 or 2- Butenyl groups are preferred.
- the halogen atom include a fluorine, chlorine, bromine and iodine atom, and a chlorine or bromine atom is preferable.
- the pyran ring formed by adjacent R t and R 2 may be substituted with a lower alkyl group having 1 to 4 carbon atoms, particularly a methyl group.
- two adjacent R 5 forming a pyridine ring are preferably on a dihydrobenzozopyran ring.
- the pyran ring formed by two adjacent R 5 may be substituted with a lower alkyl group having 14 to 14 carbon atoms, particularly a methyl group.
- R 15 is a nitro group (2′-nitro-4,, 5,5 ′, 6,7,8-hexamethoxyflavone)
- R 15 is Compounds that are amino groups (2'-amino-4,5,5 ', 6,7,8-hexamethoxyflavone) are also called V-aminonobiletin, and all are new compounds.
- the above-mentioned flavonoid compounds also include glycosides to which sugars such as iS-D-darcoside are added.
- pharmacologically, sodium, potassium, hydrochloride, etc. Acceptable salts can be formed and such salts are also included in the present invention.
- lower fatty acids such as acetic acid, propionic acid, lactic acid, and butyric acid can be added to form a pharmacologically acceptable ester, and such an ester is also included in the present invention.
- the flaponoid compound may exist in the form of a solvate such as a hydrate, and the solvate is also included in the present invention. Further, each isomer and a mixture thereof are also included in the present invention.
- the origin of the flavonoid compound of the present invention is not particularly limited, and may be of plant origin, chemically synthesized product or semi-synthetic product.
- the roots, stems, leaves, fruits, and Z or flower parts of plants may be prepared from water, methanol, lower alcohols such as ethanol, or acetone.
- a hydrophobic organic solvent such as a supercritical fluid
- a water-soluble organic solvent such as methanol.
- Power the roots, stems, and / or leaves are shredded or ground, and mixed with a lower alcohol such as methanol. It is preferred to extract.
- the flaponoid compound of the present invention can be isolated by fractionating and purifying the obtained extract using column chromatography or the like.
- the flaponoid compound of the present invention can be administered as it is, Within a range that does not reduce the amount of powder, liquid dispersion, capsules, suspensions, emulsions, syrups, elixirs, etc. It can be used in the form of oral preparations such as granules, pills, tablets, troches and limonade, or injections.
- Such carriers include water-soluble monosaccharides, oligosaccharides and polysaccharides such as mannitol, lactose and dextran; gel-forming or water-soluble such as hydroxypropyl cellulose, hydroxypropylmethylcellulose and methylcellulose.
- Cellulosics for example, crystalline cellulose, Q!
- -Cellulose cross-linking ability
- Water-absorbing and poorly water-soluble celluloses such as lipoxymethylcellulose sodium, and derivatives thereof; for example, hydroxypropyl starch, potassium propyloxymethyl starch, cross-linking
- Water-absorptive and poorly water-soluble polysaccharides such as starch, amylose, mycobacterial pectin, pectin and derivatives thereof; water-absorbable and poorly water-soluble polysaccharides such as gum arabic, tragacanth gum, daricommannan and their derivatives Gums, eg polivi
- Crosslinked vinyl polymers such as rupyrrolidone, crosslinked polyacrylic acid and salts thereof, crosslinked polyvinyl alcohol, polyhydroxyethyl methacrylate and derivatives thereof; lipids forming ribosomes such as phospholipids and cholesterol; Can be mentioned.
- a solubilization treatment can be performed.
- a solubilization treatment a method that can be generally applied to pharmaceuticals, for example, surface activity of polyoxyethylene alcohol ethers, polyoxyethylene acyl esters, sorbitan acyl esters, polyoxyethylene sorbitan acyl esters, etc. And a method using a water-soluble polymer such as polyethylene dalicol. If necessary, a method of forming a soluble salt, a method of forming an inclusion compound using cyclodextrin, or the like can be used. The method of the solubilization treatment can be appropriately changed depending on the desired flavonoid compound.
- BCRP inhibitors are used for cancers that have acquired BCRP-related resistance through administration of anticancer drugs. It can be used as an anticancer drug resistance overcoming agent. In addition, BCRP naturally expresses BCRP and can be used as an anticancer drug effect enhancer for cancers with low sensitivity to anticancer drugs.
- anticancer drug that is a target of the anticancer drug-resistance overcoming agent and the anticancer drug effect enhancer containing a BCRP inhibitor as an active ingredient, as long as it is an anticancer drug that can be a substrate of BCRP.
- irinotecan hydrochloride / CPT-11 active substance
- Topoisomerase I inhibitors such as SN-38
- topotecan topoisomerase II inhibitors
- mitoxantrone such as SN-38
- doxorubicin daunorubicin
- bisanthrene etoposide
- antifolates such as methotrexate.
- the dose of the BCRP inhibitor of the present invention may be appropriately adjusted according to the administration method, the symptoms of the patient, and the like.Adults should be administered at a dose of lmg to 10g, more preferably 100mg to 10g, particularly 500mg to 10g per day. Is preferred.
- the ratio of the anticancer agent to the BCRP inhibitor is not particularly limited, and the preferred range varies depending on the type of the anticancer agent and the inhibitor used.For example, when irinotecan hydrochloride is used as the anticancer agent, the anticancer agent: BCRP inhibitor It is preferable that the ratio of the agent is 1: 1-1: 500 in terms of weight, particularly 1: 1-1: 100, and more preferably 1: 1-1: 10.
- Table 1 Table 2, Table 3, Table 4, and Table 5 show specific examples of the flavonoid compound used in the present invention.
- Example 1 Isolation of 3 ', 5-dihydroxy-4', 6,7-trimethoxyflavone (compound 1-6)
- the C6 fraction (100.1 mg) eluted with a hexane-ethyl acetate mixed solution (2: 1) was subjected to high performance liquid chromatography CMightysil RP-18 GP, 6.OX 250 mm, acetonitrile-water (45:55) mixture As a result, a fraction having a peak at a retention time of 15.2 minutes was obtained.
- the C6 fraction was recrystallized from a mixed solution of chloroform and methanol (1: 1) to obtain 47.9 mg of compound 1-6.
- the analysis results of this compound are as follows.
- Example 2 Isolation of 5,4'-dihydroxy-6,7-dimethoxyflavone (compound 1-19) 500 g of Intinko (Inchinko) obtained from Takasago Pharmaceutical Co., Ltd. was refluxed with methanol for 2 hours. The extract was dried under reduced pressure. 5.07 g of the resulting extract (40.1 g) was spread on silica gel and eluted with hexane by medium pressure chromatography (A fraction), and then eluted with a hexane-ethyl acetate (4: 1) mixed solution ( The fraction B was eluted with ethyl acetate (fraction C), and further eluted with methanol (fraction D). The obtained C fraction
- the solid obtained was the previous crystal and ⁇ , silica gel column chromatography [manufactured by Kanto Chemical Co., Si0 2, hexane - acetic E Ji Le (1: 1) eluting with] were fractionated by.
- the desired fraction was concentrated to dryness under reduced pressure to give 2′-nitro-4 ′, 5,5 ′, 6,7,8-hexamethoxyflavone (yield 326 mg: 35%).
- the ethyl acetate layer was washed with 70 ml of saturated saline and dried over anhydrous magnesium sulfate. After magnesium sulfate was filtered off and washed with ethyl acetate, the ethyl acetate layer was concentrated to dryness under reduced pressure. The obtained solid is subjected to silica gel column chromatography [Kanto Ka Manabu made Si0 2, hexane - acetic acid Echiru (1: 1) was fractionated by eluting] in. The desired fraction was concentrated to dryness under reduced pressure to give 2′-amino-4 ′, 5,5 ′, 6,7,8-hexamethoxyflavone (yield 66 mg: 52%).
- Example 7 3,3 ', 4', 5,6,7,8-heptamethoxyflavone (compounds 1-24) and
- Example 8 Isolation of 5-hydroxy-1,6-, 7-dimethoxyflavone-1'-darcoside (Compound 1-26)
- Example 10 4H, 8H-benzo [1,2-b: 3,4-b ';] dipyran-1-4-one, 2- (2,4-dihydroxyphenyl) -1-5-hydroxy-1,8 —Dimethyl-3— (3-Methyl_2-bute Nyl) (Isolation of compound 1-28)
- the C4 fraction (217 mg) eluted in the mouth form was subjected to high performance liquid chromatography (Mightysil RP-18 GP, 6.0X 250 mm, Analysis was performed with ril-water (eluted with a 70:30 mixed solution), and a peak with a retention time of 9.8 minutes (compound 1-28) was collected.
- the analysis results of this compound are as follows.
- Example 11 Isolation of 1: 2,2,4 ', 5-trihydroxy-7-methoxy-6_ (3-methyl-1-butenyl) -13- (3-methyl-2-butenyl) -flavone (compound 29) Metabolize 169 g of Thai-produced Jack Fruit Tree (Artocarpus heterophyl lusDi $ V) The extract was extracted at room temperature for one week, and the extract was dried under reduced pressure. 4.7 g of the resulting extract (8.1 g) was eluted with hexane by medium pressure chromatography (Fraction A), and then eluted with a hexane-ethyl acetate (4: 1) mixed solution (B fraction). Subsequently, it was eluted with ethyl acetate-fraction (fraction C) and further eluted with methanol (fraction D).
- the C4 fraction (217 mg) eluted in the pore form was analyzed by high performance liquid chromatography (Mightysil RP-18 GP, 6.0X250 ram, eluted with a mixture of acetonitrile-water (70:30)). The peak at a retention time of 8.5 minutes (compound 1-29) was collected.
- the analysis results of this compound are as follows.
- the obtained B fraction (1.2 g) was analyzed by high performance liquid chromatography (Mightysil RP-18 GP, 6.0X 250 mm, eluted with a mixed solution of acetonitrile-water (70:30)). The retention time was 15.2 minutes. The fraction showing the peak of was obtained.
- the analysis results of this compound are as follows.
- Extract 8 obtained.
- 1 g 4.7 g was eluted with hexane by medium pressure chromatography (fraction A), and then eluted with a hexane-ethyl acetate (4: 1) mixed solution (fraction B).
- -Ethyl was eluted (fraction C) and further eluted with methanol (fraction D).
- the obtained C fraction 3.1 ⁇ 2 was eluted with chloroform through monitoring at 254 nm by medium pressure silica gel column chromatography, and then a chloroform-methanol (98: 2) mixed solution.
- a mixed solution of 1), (9: 1), (4: 1), (2: 1), (1: 1) and methanol was eluted in this order to obtain 10 fractions.
- the C3 fraction eluted with chloroform was analyzed by high performance liquid mouth chromatography (Migtysil RP-18 GP, 6.0X 250 thigh, eluted with a mixture of acetonitrile-water (70:30)), retention time 10.8 minutes The peak of (Compound 5-1) was collected.
- Example 14 Establishment of SN-38 resistant A549 cells
- Human non-small cell lung cancer A549 cells were prepared using Ham's F-12 medium (10% FBS / Ham's F-12) containing 10% FBS, 100 U / ml penicillin and 100 g / ml streptomycin. They were subcultured in 5% C0 2, 37 ° C conditions. SN-38 resistant A549 cells were selected by subculturing A549 cells for 2 months by gradually increasing the SN-38 concentration in the medium (4-10 ng / ml). Furthermore, cloning was performed by limiting dilution from the SN-38 resistant A549 cells, and 6 cloned SN-38 resistant A549 cells (A549 / SN-38-1 to 6) were established.
- Example 15 A549 / SN-38 cell anticancer drug sensitivity test
- the IC5Q value is the concentration of an anticancer drug that inhibits cell proliferation by 50%.
- the relative degree of resistance was IC 5 in A549 / SN-38 cells.
- IC 5 that put the value in A549 cells. This value is divided by the value, and the higher the value, the higher the resistance acquisition.
- A549 / SN-38 cells showed particularly strong resistance to BCRP substrates SN-38 and mitoxantrone.
- Example 16 RT-PCR analysis of A549 / SN-38 cells
- Total RNA was extracted from the cells using an RNA extraction reagent [IS0GEN (trade name), manufactured by Futatsu Gene], and RT-PCR reagents [Ready-To "Go RT-PCR Beads (trade name), Amersham Pharmacia” RT-PCR using Biotech (manufactured by Amersham Pharmaciabietech) and Thermocycler [manufactured by iCycler (trade name), Bio, RAD (BI0-RAD)] according to the attached procedure.
- Total RNA 0.5 g
- the PCR product was electrophoresed on a 2% agarose gel, stained with ethidium umide, and detected with a transilluminator.
- RT-PCR results are shown in Fig. 2 and the real-time RT-PCR results are shown.
- the results are shown in Figure 3.
- BCHP expression was significantly increased in all six A549 / SN-38 cells compared to A549 cells, while the expression level of MRP2 using SN-38 as a substrate as in BCRP. No significant differences were found in the expression levels of other drug transport proteins between A549 cells and A549 / SN-38 cells. -38 may be involved in anticancer drug resistance mechanism Was instigation.
- BCRP expression was also confirmed BCRP expression in human breast cancer MCF 7 cells.
- topoisomerase-1 in addition to the expression of drug-transporting protein, the expression of topoisomerase-1, topoisomerase-11, Beto 2, Bax and I ⁇ was analyzed by Western blot for topoisomerase-1 activity. DM relaxation response was examined as an index, but these were A549 / SN-38 cells resistant to anticancer drugs. No data was suggested to implicate the mechanism.
- Example 17 A549 / SN-38 cell accumulation of anticancer drug
- SN-38 DMS0 solution 1 1 (final concentration: 300 ng / ml) in 1 ml of 10% FBS / RPMI 1640 suspended A549 cells or A549 / SN-38-4 cells (4 x 10 6 cel ls / ml) was added and incubated at 37 ° C for 60 minutes, followed by centrifugation (2 ° C, 1,400 X g, 1 min) to remove the supernatant. The precipitated cells were resuspended by adding ice-cold PBS, and centrifuged (2 ° C, 1,400 Xg, 1 min) to wash the cells. After performing this washing operation one more time, PBS 375 xl was added thereto to destroy the cells by ultrasonic treatment.
- Example 18 Effect of flavonoid compound on the resistance of A549 / SN-38 cells to anticancer drugs
- A549 cells or A549 / SN- 38- 4 cells were suspended in 10% FBS / Ham 's F- 12, 96 Ueru microplate seeding cultured in 5% C0 2, 37 ° C under conditions (2 10 3 ce lls / 50 l / we ll). After chromatography ⁇ culture, flavonoid compounds and SN - 38 dissolved 10% FBS / H am 's F- 12 respectively 25 1, and the mixture was incubated for 48 hours at 5% C0 2, 37 ° C conditions. After the culture, the number of viable cells was measured using TetraColor ONE according to the attached operation procedure. EC 5 resistance overcoming effect of each Furaponoido compounds in Table 7. Indicated by value. In addition, EC 5.
- the value is the concentration of the flavonoid compound at which the relative tolerance is reduced by 50%.
- the flavonoid compound showed a strong overcoming effect on SN-38 resistance of A549 / SN-38-4 cells.
- the flaponoid compound itself did not affect the growth of A549 cells and A549 / SN-38-4 cells in the concentration range that overcomes the resistance in a concentration-dependent manner. This result suggests that the flaponoid compound of the present invention inhibits BCRP and overcomes anticancer drug resistance of cancer cells.
- Example 20 Effect of flaponoid compound on anticancer drug resistance of human BCRP transgenic mouse leukemia P388 cells
- Mouse leukemia ⁇ 88 cells or human BCRP transgenic P388 cells (P388 / BCRP cells, obtained from Yoshikazu Sugimoto, Cancer Chemotherapy Center, Cancer Society of Japan) suspended in 10% FBS / RPMI 1640 96-well microphone plate after seeding in (1 X 10 4 cel ls / 50
- Example 21 Effect of flavonoid compound on multidrug resistance of MES-SA / DX5 cells Human uterine cancer MES-SA cells or MES-SA / Dx5 cells which overexpressed P-glycoprotein and acquired multidrug resistance (Cancer Res. 45, 4091-4096 ( 1985)) was suspended in 10% FBS / DMEM, and cultured in 5% C0 2, 37 ° C conditions, were seeded in 9 6-well microphone opening plate (3 X 10 3 ce l ls / 50 ⁇ I / wel l).
- Furaponoido compound and paclitaxel dissolve the the 10% FBS / DMEM, respectively 25, and the mixture was incubated for 48 hours at 5% C0 2, 37 ° C conditions. After the culture, the number of viable cells was measured using TetraColor ONE according to the attached operation procedure. The effect on multidrug resistance of each Furabonoido compound shown by the EC 5Q values in Table 9. In addition, EC 5. The value is the concentration of the flavonoid compound at which the relative tolerance is reduced by 50%. As a result, flavonoid compounds did not affect paclitaxel resistance of MES-SA / Dx5 cells in the concentration range examined.
- the flavonoid compound itself did not affect the proliferation of MES-SA cells and HES-SA / DX5 cells.
- the results showed that the flavonoid compound of the present invention did not act on P-glycoprotein and had specificity for BCRP.
- Table 9 Compounds Overcoming resistance
- P388 cells and P388 / BCRP cells (1 10 7 cel ls / ml ), or MCF-7 cells (3 x 10 6 cel ls / ml)
- Furaponoido compound 10% FBS / RPMI 1640 1ml was suspended and SN - 38 (Final concentration: 500 ng / ml), incubated at 37 ° C for 60 minutes, and centrifuged (2 ° C, 1,400 X g, 1 min) to remove the supernatant. After ice-cold 10% FBS / RPMI 1640 was added to the precipitated cells and resuspended, the cells were washed by centrifugation (2, 1, 400 xg, 1 min).
- PBS 3751 was added and the cells were disrupted by sonication.
- methanol 3751 and 15 l of a 10% zinc sulfate solution were added, stirred, and then centrifuged (2 ° C, 12,500 X g, 5 min) to collect a supernatant.
- the amount of SN-38 in the supernatant was measured using a microplate fluorometer (SN-38: The excitation wavelength was 380 nm and the measurement wavelength was 560 nm), and the amount accumulated in the cells was calculated.
- the flaponoid compound of the present invention was accumulated in SN388 cells of P388 / BCRP cells. Increased capacity. Further, as shown in FIG. 7, the flaponoid compound of the present invention increased the amount of SN-38 accumulated in MCF-7 cells. This result suggests that the flavonoid compound of the present invention inhibits BCKP and increases the amount of an anticancer agent taken up into cells.
- Example 23 Effect of overcoming anticancer drug resistance of flaponoid compounds in vivo
- P388 cells or P388 / BCRP (1 ⁇ 10 6 cells / mouse) were transplanted intraperitoneally into 6-week-old CDF, strain, female mice (5 / group), and flavonoid compounds and irinotecan hydrochloride (CPT-11) were implanted.
- CPT-11 flavonoid compounds and irinotecan hydrochloride
- the survival days of the mice after tumor transplantation were examined, and the survival rate T / C (%) was calculated from the following formula to determine the antitumor effect.
- Example 24 The following components were mixed, and the mixture was tableted.
- the present invention makes it possible to overcome BCRP-related anticancer drug resistance. It is also possible to enhance the effects of anticancer drugs against BCRP-expressing cancers. Furthermore, it is expected to improve the bioavailability of anticancer drugs, which is expected to lead to an improvement in treatment results in cancer chemotherapy.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/544,062 US20060135445A1 (en) | 2003-02-04 | 2004-02-03 | Breast cancer-resistant protein inhibitor |
CA002515135A CA2515135A1 (en) | 2003-02-04 | 2004-02-03 | Breast cancer-resistant protein inhibitor |
JP2005504830A JPWO2004069233A1 (ja) | 2003-02-04 | 2004-02-03 | 乳癌耐性蛋白阻害剤 |
EP04707627A EP1591112A4 (en) | 2003-02-04 | 2004-02-03 | INHIBITOR OF BREAST CANCER RESISTANT PROTEIN |
US12/181,957 US20080287374A1 (en) | 2003-02-04 | 2008-07-29 | Breast cancer-resistant protein inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003026857 | 2003-02-04 | ||
JP2003-026857 | 2003-02-04 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/181,957 Division US20080287374A1 (en) | 2003-02-04 | 2008-07-29 | Breast cancer-resistant protein inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004069233A1 true WO2004069233A1 (ja) | 2004-08-19 |
Family
ID=32844155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/001054 WO2004069233A1 (ja) | 2003-02-04 | 2004-02-03 | 乳癌耐性蛋白阻害剤 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20060135445A1 (ja) |
EP (1) | EP1591112A4 (ja) |
JP (1) | JPWO2004069233A1 (ja) |
KR (1) | KR20050095859A (ja) |
CN (1) | CN1744887A (ja) |
CA (1) | CA2515135A1 (ja) |
TW (1) | TW200505890A (ja) |
WO (1) | WO2004069233A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006025431A1 (ja) * | 2004-08-31 | 2006-03-09 | Japanese Foundation For Cancer Research | 抗癌剤耐性克服剤 |
WO2006106778A1 (ja) * | 2005-03-30 | 2006-10-12 | Kabushiki Kaisha Yakult Honsha | Bcrp/abcg2阻害剤 |
JP2009051738A (ja) * | 2007-08-23 | 2009-03-12 | Yasuhara Chemical Co Ltd | ポリメトキシフラボン類の製造方法、その方法で得られるポリメトキシフラボン類、およびポリメトキシフラボン類含有有機酸水溶液 |
WO2009072267A1 (ja) | 2007-12-03 | 2009-06-11 | Kabushiki Kaisha Yakult Honsha | Abcg2阻害剤 |
JP2009203207A (ja) * | 2008-02-29 | 2009-09-10 | Hiroshima Univ | 新規生理活性組成物 |
JP2013541557A (ja) * | 2010-10-22 | 2013-11-14 | エイピーアイ・ジェネシス,エルエルシー | 可溶性の乏しい化合物の可溶性を増大させる方法ならびにそのような化合物の配合物を作る、および用いる方法 |
WO2021215517A1 (ja) | 2020-04-22 | 2021-10-28 | ネオファーマジャパン株式会社 | 新型コロナウイルス感染症(covid-19)の治療及び/又は予防剤 |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5380069B2 (ja) * | 2005-03-11 | 2014-01-08 | ハワード フローリー インスティチュート | フラボノイド化合物およびその使用 |
WO2009070331A2 (en) * | 2007-11-27 | 2009-06-04 | Stc.Unm | Compounds and methods for the selective inhibition of abcb1, abcc1 and abcg2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors |
FR2941456B1 (fr) * | 2009-01-26 | 2011-03-04 | Univ Claude Bernard Lyon | Nouveaux composes de type azapeptide ou azapeptidomimetrique inhibiteurs de bcrp et/ou p-gp. |
CN102180853B (zh) * | 2011-03-09 | 2013-03-27 | 中国科学院昆明植物研究所 | 抗ev71的黄酮类化合物,及其在制药中的应用 |
CN102267888B (zh) * | 2011-06-14 | 2014-02-26 | 黑龙江大学 | 制备查尔酮衍生物的方法 |
RU2640913C2 (ru) * | 2011-09-07 | 2018-01-12 | Дойчес Кребсфоршунгсцентрум | Средства и способы лечения и/или предотвращения рака, зависимого от природного лиганда ahr |
EP2889038B1 (en) | 2012-08-31 | 2016-10-19 | Korea Research Institute of Bioscience and Biotechnology | Composition for preventing or treating cancer containing extracts of artocarpus altilis fruits, leaves, or stems, or fractions thereof as active ingredients |
CN102861069B (zh) * | 2012-10-27 | 2013-08-28 | 南京大学 | Houttuynoid B在治疗喉癌药物中的应用 |
CN102861056B (zh) * | 2012-10-27 | 2013-08-28 | 吴俊华 | Houttuynoid A在治疗子宫内膜癌药物中的应用 |
CN102872078B (zh) * | 2012-10-27 | 2013-07-17 | 吴俊华 | Houttuynoid C在治疗白血病药物中的应用 |
CN102872135B (zh) * | 2012-10-27 | 2013-07-17 | 吴俊华 | Houttuynoid D在治疗肾癌药物中的应用 |
CN102861049B (zh) * | 2012-10-27 | 2013-08-28 | 吴俊华 | Houttuynoid A在治疗肝癌药物中的应用 |
CN102872098B (zh) * | 2012-10-27 | 2013-07-17 | 吴俊华 | Houttuynoid A在预防、治疗肾功能不全药物中的应用 |
CN102861070B (zh) * | 2012-10-27 | 2013-08-28 | 南京大学 | Houttuynoid E在治疗舌癌药物中的应用 |
CN102861089B (zh) * | 2012-10-27 | 2013-08-28 | 吴俊华 | Houttuynoid B在治疗肝癌药物中的应用 |
CN102872134B (zh) * | 2012-10-27 | 2013-10-23 | 吴俊华 | Houttuynoid D在治疗喉癌药物中的应用 |
CN102861058B (zh) * | 2012-10-27 | 2013-08-28 | 吴俊华 | Houttuynoid D在治疗胆管癌药物中的应用 |
CN102872125B (zh) * | 2012-10-27 | 2013-08-28 | 吴俊华 | Houttuynoid C在治疗宫颈癌药物中的应用 |
CN102872143B (zh) * | 2012-10-27 | 2013-12-18 | 吴俊华 | Houttuynoid D在预防或治疗胰腺纤维化的药物中的应用 |
CN102872108B (zh) * | 2012-10-27 | 2013-07-17 | 吴俊华 | Houttuynoid A在治疗胆管癌药物中的应用 |
CN102861065B (zh) * | 2012-10-27 | 2013-08-28 | 吴俊华 | Houttuynoid E在治疗胃癌药物中的应用 |
CN102872113B (zh) * | 2012-10-27 | 2013-08-28 | 吴俊华 | Houttuynoid A在治疗白血病药物中的应用 |
CN102861093B (zh) * | 2012-10-27 | 2013-08-28 | 吴俊华 | Houttuynoid B在治疗结直肠癌药物中的应用 |
US10865176B2 (en) | 2012-12-21 | 2020-12-15 | The Chinese University Of Hong Kong | Small molecule modulators of microRNA-34a |
CN103877069B (zh) * | 2012-12-21 | 2017-01-04 | 香港中文大学 | 微RNA‑34a的小分子调节剂 |
ITRM20130366A1 (it) * | 2013-06-25 | 2014-12-26 | Univ Roma La Sapienza | Multitarget hedgehog pathway inhibitors and uses thereof |
CN110151751B (zh) * | 2019-05-14 | 2023-07-28 | 山东中医药大学 | 岩豆素在制备用于防治与5-脂氧合酶相关疾病的药物中的应用 |
US20220356162A1 (en) * | 2019-06-19 | 2022-11-10 | Dr. Reddy's Institute Of Life Sciences | Heterocyclic Compounds as Lipoxygenase Inhibitors |
CN110818755B (zh) * | 2019-11-28 | 2022-11-11 | 海南大学 | 一种金花茶中提取的化合物及其制药应用 |
CN113045527B (zh) * | 2021-03-22 | 2022-11-08 | 广东省科学院动物研究所 | 二氢色原酮衍生物及其合成方法和用途 |
CN115813991A (zh) * | 2022-11-29 | 2023-03-21 | 三峡大学 | 一种柑橘属果实提取物在制备治疗乳腺癌内分泌药物中的应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0074256A1 (en) * | 1981-09-04 | 1983-03-16 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives, processes for preparing same, formulations containing such derivatives and their use |
JPH0570348A (ja) * | 1991-09-14 | 1993-03-23 | Kureha Chem Ind Co Ltd | 多剤耐性抑制剤 |
WO1999040110A1 (en) * | 1998-02-05 | 1999-08-12 | University Of Maryland, Baltimore | Breast cancer resistance protein (bcrp) and the dna which encodes it |
WO1999043676A2 (en) * | 1998-02-26 | 1999-09-02 | Aventis Pharmaceuticals Inc. | 6,9-disubstituted 2-[trans-(4- aminocyclohexyl) amino]purines |
WO2000019998A1 (en) * | 1998-10-06 | 2000-04-13 | Kgk Synergize | Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin |
EP1159963A1 (en) * | 2000-06-02 | 2001-12-05 | Protein Technologies International, Inc. | Composition for and method of preventing or treating breast cancer |
JP2001342132A (ja) * | 2000-06-05 | 2001-12-11 | Protein Technol Internatl Inc | 乳癌を予防し、もしくは治療するための組成物およびそのための方法 |
JP2003040781A (ja) * | 2001-07-26 | 2003-02-13 | Ezaki Glico Co Ltd | 飲食物および医薬品 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5336685A (en) * | 1993-04-12 | 1994-08-09 | Sloan-Kettering Institute For Cancer Research | Use of flavonoids to treat multidrug resistant cancer cells |
WO2001007034A1 (en) * | 1999-07-23 | 2001-02-01 | Colorado State University Research Foundation | Multidrug resistance pump inhibitors and uses thereof |
GB9920912D0 (en) * | 1999-09-03 | 1999-11-10 | Indena Spa | Novel derivatives of flavones,xanthones and coumarins |
-
2004
- 2004-02-03 US US10/544,062 patent/US20060135445A1/en not_active Abandoned
- 2004-02-03 EP EP04707627A patent/EP1591112A4/en not_active Withdrawn
- 2004-02-03 CN CNA2004800032933A patent/CN1744887A/zh active Pending
- 2004-02-03 WO PCT/JP2004/001054 patent/WO2004069233A1/ja active Search and Examination
- 2004-02-03 JP JP2005504830A patent/JPWO2004069233A1/ja active Pending
- 2004-02-03 KR KR1020057013461A patent/KR20050095859A/ko not_active Application Discontinuation
- 2004-02-03 CA CA002515135A patent/CA2515135A1/en not_active Abandoned
- 2004-02-04 TW TW093102518A patent/TW200505890A/zh unknown
-
2008
- 2008-07-29 US US12/181,957 patent/US20080287374A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0074256A1 (en) * | 1981-09-04 | 1983-03-16 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives, processes for preparing same, formulations containing such derivatives and their use |
JPH0570348A (ja) * | 1991-09-14 | 1993-03-23 | Kureha Chem Ind Co Ltd | 多剤耐性抑制剤 |
WO1999040110A1 (en) * | 1998-02-05 | 1999-08-12 | University Of Maryland, Baltimore | Breast cancer resistance protein (bcrp) and the dna which encodes it |
WO1999043676A2 (en) * | 1998-02-26 | 1999-09-02 | Aventis Pharmaceuticals Inc. | 6,9-disubstituted 2-[trans-(4- aminocyclohexyl) amino]purines |
WO2000019998A1 (en) * | 1998-10-06 | 2000-04-13 | Kgk Synergize | Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin |
EP1159963A1 (en) * | 2000-06-02 | 2001-12-05 | Protein Technologies International, Inc. | Composition for and method of preventing or treating breast cancer |
JP2001342132A (ja) * | 2000-06-05 | 2001-12-11 | Protein Technol Internatl Inc | 乳癌を予防し、もしくは治療するための組成物およびそのための方法 |
JP2003040781A (ja) * | 2001-07-26 | 2003-02-13 | Ezaki Glico Co Ltd | 飲食物および医薬品 |
Non-Patent Citations (3)
Title |
---|
BRANGI ET AL.,: "Camptothecin resistance: role of the ATP-binding cassette (ABC), Mitoxantrone-resistance Half-transporter (MXR), and potential for glucuronidation in MXR-exüressing cells.", CANCER RES., vol. 59, no. 23, 1999, pages 5938 - 5946, XP002977699 * |
DOYLE, L. A. ET AL.: "A multidrug resistance transporter from human MCF-7 breast cancer cells", PROC. NATL. ACAD. SCI., vol. 95, no. 26, 1998, pages 15665 - 15670, XP002919721 * |
See also references of EP1591112A4 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006025431A1 (ja) * | 2004-08-31 | 2006-03-09 | Japanese Foundation For Cancer Research | 抗癌剤耐性克服剤 |
JP2006069910A (ja) * | 2004-08-31 | 2006-03-16 | Yoshiichi Sugimoto | 抗癌剤耐性克服剤 |
WO2006106778A1 (ja) * | 2005-03-30 | 2006-10-12 | Kabushiki Kaisha Yakult Honsha | Bcrp/abcg2阻害剤 |
EA014555B1 (ru) * | 2005-03-30 | 2010-12-30 | Кабусики Кайся Якулт Хонса | Ингибитор bcrp/abcg2 |
EP2332905A1 (en) | 2005-03-30 | 2011-06-15 | Kabushiki Kaisha Yakult Honsha | BCRP/ABCG3 Inhibitor |
US8697742B2 (en) | 2005-03-30 | 2014-04-15 | Kabushiki Kaisha Yakult Honsha | BCRP/ABCG2 inhibitor |
NO343883B1 (no) * | 2005-03-30 | 2019-07-01 | Yakult Honsha Kk | BCRP/ABCG2 inhibitor |
JP2009051738A (ja) * | 2007-08-23 | 2009-03-12 | Yasuhara Chemical Co Ltd | ポリメトキシフラボン類の製造方法、その方法で得られるポリメトキシフラボン類、およびポリメトキシフラボン類含有有機酸水溶液 |
WO2009072267A1 (ja) | 2007-12-03 | 2009-06-11 | Kabushiki Kaisha Yakult Honsha | Abcg2阻害剤 |
JP2009203207A (ja) * | 2008-02-29 | 2009-09-10 | Hiroshima Univ | 新規生理活性組成物 |
JP2013541557A (ja) * | 2010-10-22 | 2013-11-14 | エイピーアイ・ジェネシス,エルエルシー | 可溶性の乏しい化合物の可溶性を増大させる方法ならびにそのような化合物の配合物を作る、および用いる方法 |
WO2021215517A1 (ja) | 2020-04-22 | 2021-10-28 | ネオファーマジャパン株式会社 | 新型コロナウイルス感染症(covid-19)の治療及び/又は予防剤 |
Also Published As
Publication number | Publication date |
---|---|
CA2515135A1 (en) | 2004-08-19 |
JPWO2004069233A1 (ja) | 2006-05-25 |
EP1591112A1 (en) | 2005-11-02 |
KR20050095859A (ko) | 2005-10-04 |
US20080287374A1 (en) | 2008-11-20 |
TW200505890A (en) | 2005-02-16 |
CN1744887A (zh) | 2006-03-08 |
EP1591112A4 (en) | 2006-06-14 |
US20060135445A1 (en) | 2006-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004069233A1 (ja) | 乳癌耐性蛋白阻害剤 | |
Hu et al. | Benzophenanthridine alkaloids from Zanthoxylum nitidum (Roxb.) DC, and their analgesic and anti‐inflammatory activities | |
Yang et al. | Phenolic compounds with radical scavenging and cyclooxygenase-2 (COX-2) inhibitory activities from Dioscorea opposita | |
Ku et al. | Angustilobine and andranginine type indole alkaloids and an uleine–secovallesamine bisindole alkaloid from Alstonia angustiloba | |
CN109134586B (zh) | 雷公藤红素衍生物及其应用 | |
Boonyaketgoson et al. | Cytotoxic arylbenzofuran and stilbene derivatives from the twigs of Artocarpus heterophyllus | |
Yu et al. | Two new alkaloid metabolites produced by endophytic fungus Stagonosporopsis oculihominis isolated from Dendrobium huoshanense | |
Guo et al. | Triterpenoids and meroterpenoids with α-glucosidase inhibitory activities from the fruiting bodies of Ganoderma australe | |
Yao et al. | Stereoisomeric guaiacylglycerol-β-coniferyl aldehyde ether induces distinctive apoptosis by downregulation of MEK/ERK pathway in hepatocellular carcinoma cells | |
Yu et al. | An Aspidosperma-type alkaloid dimer from Tabernaemontana bovina as a candidate for the inhibition of microglial activation | |
Tian et al. | Natural sesquiterpene quinone/quinols: chemistry, biological activity, and synthesis | |
TWI580689B (zh) | 甾醇類衍生物及其製備方法與應用 | |
Aghaei et al. | Pimpinelol, a novel atypical sesquiterpene lactone from Pimpinella haussknechtii fruits with evaluation of endoplasmic reticulum stress in breast cancer cells | |
CN102516344A (zh) | 一种具有抗肿瘤活性的化合物及其制备方法和应用 | |
Zi et al. | New cannabidiol (CBD) derivatives: Synthesis, anti-inflammatory activity, and molecular docking | |
JP2005330261A (ja) | 腫瘍/癌細胞の増殖の抑制活性を有するガンボージ樹脂から単離した化合物及びその化合物を含む薬学的組成物 | |
CN101889998B (zh) | 一种组合物及其在制备tr3受体诱导剂中的应用 | |
JP4769959B2 (ja) | 抗腫瘍剤 | |
Dupommier et al. | New desulfured troglitazone derivatives: improved synthesis and biological evaluation | |
KR20140108796A (ko) | 등심초 추출물을 유효 성분으로 포함하는 항암 효과를 갖는 약제학적 조성물 | |
KR102160471B1 (ko) | 화합물뿐만 아니라 그의 분리 방법, 합성 방법 및 용도 | |
JP5478082B2 (ja) | インターロイキン−2産生抑制剤 | |
KR101745504B1 (ko) | 잠분으로부터 항암 활성을 갖는 보미폴리올 및 스티그마스테롤을 분리하는 방법 | |
El Antri et al. | Structure elucidation and vasodilator activity of methoxy flavonols from Calycotome villosa subsp. intermedia | |
JP2669762B2 (ja) | 2―(1―ヒドロキシエチル)―5―ヒドロキシナフト〔2,3―b〕フラン―4,9―ジオンを含有する発癌プロモーション阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005504830 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057013461 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004707627 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048032933 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2006135445 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10544062 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2515135 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057013461 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004707627 Country of ref document: EP |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 10544062 Country of ref document: US |